HVR Cardio raises $11.1M in Series B financing round

HVR Cardio announced that it closed a Series B round of financing worth €10.7 million ($11.1 million) in proceeds.

Innovestor Life Science Fund and Tesi led the financing round. HVR Cardio declined to disclose its planned use(s) for the proceeds.

Helsinki, Finland-based HVR Cardio develops transcatheter mitral valve repair (TMVR) solutions based on its proprietary helix technology. Its CathHelix device remains investigational in all geographies.

“MR is a common valvular heart disease impacting millions of people and leaving a significant need for better treatment options,” said Pekka Simula, Innovestor partner. We are truly excited about the elegant and minimally invasive CathHelix technology that will offer new hope for patients.”

HVR Cardio also announced a new leadership team to accompany the financing round.

Tom Fleming joined the company as CEO in May 2022. He brings with him 21 years of experience from Boston Scientific. He ended his time there as VP and GM for Boston Scientific’s structural heart valve business. Before that, he served as CEO of 4Tech.

Additionally, HVR Cardio hired another Boston Scientific veteran, Tim Girton, as chief technology officer in July 2022. Girton spent more than 23 years at Boston Scientific. He concluded his tenure there as VP of R&D in the company’s interventional cardiology arm. MassDevice